Foundayo vs Wegovy Pill: Which Oral GLP-1 Is Right for You?

2026 is the year the GLP-1 weight loss market went oral. Foundayo (orforglipron from Eli Lilly) was FDA-approved on April 1, 2026 (FDA press release), joining the Wegovy pill (oral semaglutide 25mg from Novo Nordisk), which got the green light on December 22, 2025 (Novo Nordisk announcement). Both are FDA-approved for chronic weight management. Both are now stocked by major telehealth platforms. And as of early May 2026, CNBC reports the Wegovy pill is outpacing Foundayo in early prescriptions, while Lilly says more than 20,000 people started Foundayo in its first month. So if you're trying to decide between them, you're not alone. Here's an honest head-to-head.

The Short Answer

Both pills are once-daily, both are FDA-approved for adults with obesity or overweight with weight-related conditions, and both work by mimicking the GLP-1 hormone that signals fullness.

• Wegovy Pill (oral semaglutide 25mg, Novo Nordisk): approximately 13.6% mean body weight loss at 25mg in the OASIS 4 trial (Novo Nordisk, December 2025). Established molecule with a multi-year track record from the injectable form.
• Foundayo (orforglipron, Eli Lilly): approximately 11.1% mean weight loss across all participants and 12.4% among trial completers at the highest dose in the ATTAIN-1 trial (Eli Lilly, April 2026). Newer molecule, but the only oral GLP-1 with no food, water, or timing restrictions.
• Novo's ORION indirect comparison analysis (April 2026) estimates oral semaglutide produces about 3 percentage points more weight loss than orforglipron (Novo Nordisk press release). No head-to-head randomized trial exists.

If you want maximum published efficacy, Wegovy pill has the edge. If you want flexibility in your daily routine, Foundayo wins. The rest is detail.

What Each Drug Actually Is

Wegovy Pill is an oral formulation of semaglutide, the same active molecule used in injectable Wegovy and in Ozempic. To get a peptide drug across the gut lining, Novo pairs the semaglutide with an absorption enhancer called SNAC. The maintenance dose is 25mg once daily (wegovy.com pill guide).

Foundayo is orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. It's the first non-peptide GLP-1 to reach market, and the first new molecular entity approved under the FDA's National Priority Voucher Program (FDA press release, April 2026). Because it's a small molecule rather than a peptide, it doesn't need an absorption enhancer and isn't degraded by stomach acid the same way semaglutide is.

Both are FDA-approved finished products. Neither requires the regulatory caveats that apply to compounded oral GLP-1s.

Efficacy: What the Trials Actually Show

The honest comparison here is harder than it looks because the two drugs have never been studied head-to-head.

Wegovy pill (OASIS 4): A 64-week phase 3b trial of once-daily oral semaglutide 25mg versus placebo in 307 adults with obesity or overweight plus one or more comorbidities. Mean weight loss across all participants was approximately 13.6%, compared to about 2.4% for placebo. Among adherent participants, weight loss reached 16.6% (Novo Nordisk, December 2025).

Foundayo (ATTAIN-1): A 72-week phase 3 trial. Across all participants, mean weight loss was approximately 11.1% (about 25 lbs) at the highest dose. Among participants who completed treatment at the highest dose, weight loss reached 12.4% (about 27.3 lbs). Placebo lost 0.9% to 2.1% depending on the analysis (Eli Lilly, April 2026).

The ORION indirect comparison: In April 2026, Novo Nordisk presented a population-adjusted indirect treatment comparison at the Obesity Medicine Association annual conference. ORION used data from OASIS 4 and ATTAIN-1 to estimate that oral semaglutide 25mg produced about 3.2 additional percentage points of weight loss compared to orforglipron 36mg under real-world conditions, and 3.0 percentage points under full-adherence conditions (Novo Nordisk press release).

Two important caveats on ORION. First, it is an indirect comparison, not a randomized trial, so the populations and protocols of OASIS 4 and ATTAIN-1 had to be statistically adjusted to make the comparison possible. Second, the analysis was funded and conducted by Novo Nordisk, the maker of one of the two drugs being compared. Until an independent head-to-head trial is published, treat the 3-percentage-point gap as a directional estimate, not a settled fact.

Daily Routine: Foundayo's Strongest Case

If the efficacy gap is real but modest, the daily routine difference is concrete and unavoidable.

Wegovy pill instructions are strict. Take it first thing in the morning, on an empty stomach, with no more than 4 ounces of plain water (not coffee, not juice, just water). Then wait at least 30 minutes before food, any other beverage, or other oral medications. Swallow the pill whole; do not crush, cut, chew, or dissolve it (wegovy.com pill guide). If you take other morning medications, you have to time them around the Wegovy window. If you're someone who reaches for coffee within ten minutes of waking up, you'll have to break that habit on Wegovy pill days, which is every day.

Foundayo has none of these constraints. It can be taken any time of day, with or without food, with whatever liquid you want, and without timing relative to other medications (Eli Lilly press release). For patients with morning routines built around coffee, prescription medications, or breakfast, that flexibility is meaningful.

The practical implication: a meaningful subset of patients will lose effective dose exposure on Wegovy pill simply because the instructions are hard to follow consistently. Foundayo removes that variable.

Cost Comparison

Both drugs are priced aggressively for the cash-pay market, and both have commercial insurance savings cards that can drop costs to as low as $25/month for eligible patients.

	Wegovy Pill (semaglutide)	Foundayo (orforglipron)
Manufacturer cash price	$149/mo for the 1.5mg and 4mg doses through NovoCare (verify dose-specific pricing for higher doses on novocare.com)	$149/mo at 0.8mg, $199/mo at 2.5mg, $299/mo at 5.5mg and 9mg; 14.5mg and 17.2mg at $349/mo or $299/mo with 45-day refills via the Self-Pay Savings Program
Commercial insurance savings program	As low as $25/mo, max savings $100 per fill	As low as $25/mo for eligible commercially insured patients
FDA approval date	December 22, 2025	April 1, 2026

Manufacturer pricing per NovoCare and LillyDirect Foundayo (May 2026); savings program details per NovoCare savings offer.

Telehealth providers can be cheaper than going direct to the manufacturer, especially at maintenance doses. Here's where our reviewed providers land:

Provider	Wegovy Pill	Foundayo	Notes
Found	$198/mo all-inclusive	From $149/mo (escalates by dose)	No separate membership fee
Hers	$149/mo + $149/mo membership ($39 first month)	$149/mo + $149/mo membership ($39 first month)	Women-focused; Novo Nordisk partner
Shed	$149/mo + $125/mo Shed Membership	$149/mo + $125/mo Shed Membership	Widest format diversity reviewed
Hims	$149/mo + $149/mo membership	Not currently stocked	Novo Nordisk partner; Wegovy pill only

For a live filterable view of provider pricing across all GLP-1 medications including both pills, see our GLP-1 pricing tool and the current cheapest GLP-1 monthly report.

Side Effects: More Alike Than Different

Both drugs share the GLP-1 class side effect profile: nausea, vomiting, constipation, and diarrhea, mostly mild-to-moderate, and most concentrated during dose escalation (wegovy.com; Eli Lilly).

Novo's ORION analysis reported that orforglipron was associated with about 14 times higher odds of stopping treatment due to side effects than the Wegovy pill in the indirect comparison (Novo Nordisk press release). The same caveats apply: indirect comparison, manufacturer-funded, not a head-to-head trial. Real-world tolerability data over the next 12 to 18 months will tell the more honest story.

Standard advice applies for either drug: titrate slowly, hydrate aggressively, prioritize lean protein, and call your prescriber if symptoms become severe or persistent. For more on what to expect, see our GLP-1 side effects guide.

Switching From an Injectable

If you're already on an injectable GLP-1 and considering an oral switch, the data from Lilly's ATTAIN-MAINTAIN trial is worth knowing.

• Wegovy injection to Foundayo: patients regained on average 0.9 kg (roughly 2 lbs) over the year, a small fraction of the typical Wegovy injection weight loss (Eli Lilly press release on ATTAIN-MAINTAIN).
• Zepbound (tirzepatide) injection to Foundayo: patients regained on average 5.0 kg (roughly 11 lbs) over the year, a meaningfully larger share of typical Zepbound weight loss.
• Wegovy injection to Wegovy pill: same molecule, no class change. Generally a smoother transition with minimal expected regain, though no specific switch trial has been published.

The Zepbound-to-Foundayo gap is mechanistically explained: Zepbound activates both GLP-1 and GIP receptors, while Foundayo activates only GLP-1. You can't fully replicate dual-receptor effects with a single-receptor pill. If you're responding well to tirzepatide, the published evidence argues for staying on it. For more on tirzepatide vs semaglutide as molecules, see our tirzepatide vs semaglutide comparison.

Who Should Choose Wegovy Pill

• You want the higher published efficacy (about 13.6% vs about 11.1% mean weight loss).
• You're already on injectable Wegovy and want to switch formats with minimal regain.
• You can stick to the morning-empty-stomach routine with discipline (no coffee, no breakfast, no other medications for 30 minutes after dosing).
• You want the longer real-world track record. Semaglutide has been on the market in some form for years; orforglipron just launched.

Who Should Choose Foundayo

• You can't or won't reliably take a pill on an empty stomach with timing constraints.
• You take other morning medications and need scheduling flexibility.
• You're starting fresh and aren't already responding to a different GLP-1.
• You prefer a non-peptide molecule (a niche consideration relevant for some patients with peptide sensitivity).
• You value the option to take the pill any time of day, including with food.

See the Live Pricing

Provider pricing changes month to month, especially at this stage of the oral GLP-1 launch. Our GLP-1 pricing tool shows current prices across all reviewed providers, filterable by medication type and delivery format. If oral GLP-1s are what you want, you can filter directly to Foundayo and Wegovy pill listings to see today's numbers.

For more context on how the two pills fit into the broader GLP-1 landscape, see our companion guides on Wegovy vs Ozempic, injectable vs oral GLP-1, and GLP-1 options without needles.

The Bottom Line

Wegovy pill has the higher published efficacy, the longer molecular track record, and the manufacturer's own indirect comparison analysis suggesting a 3-percentage-point edge. But that edge comes with a strict morning routine that's easy to mess up. Foundayo trades a few percentage points of average weight loss for total flexibility on when and how you take it, which for many patients will translate to better real-world adherence.

If you have insurance that covers either, take the one with the better savings card terms for your plan and call it a day. If you're paying cash and you're disciplined about routine, Wegovy pill at the maintenance dose is the higher-efficacy choice. If you're paying cash and you want a pill you can take with breakfast, Foundayo is the obvious pick.

Both require a prescription and a licensed prescriber evaluation. Talk to a healthcare provider about which fits your medical history, current medications, and weight loss goals. If you want help narrowing down which telehealth provider to use, our 10-question quiz takes about three minutes and produces a personalized ranking.